Future Science OA最新文献_第2页

Chylothorax as a rare complication of COVID-19: a case report. 乳糜胸作为COVID-19的罕见并发症：1例报告。

IF 2.1

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-09-15 DOI: 10.1080/20565623.2025.2560267

Asma Knaz, Iteb Ben Limem, Sana Aissa, Amina Abdelkbir, Adel Marghli, Ahmed Abdelghani

引用次数: 0

Comparison of biomarkers and laboratory results in unaffected, moderate, and severe COVID-19 recovered patients. 未受影响、中度和重度COVID-19康复患者的生物标志物和实验室结果比较

IF 2.1

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-09-18 DOI: 10.1080/20565623.2025.2559553

Sawsan Abuhammad, Karem H Alzoubi, Omar F Khabour, Shaher Hamaideh, Basheer Khassawneh, Amat Al-Khaleq O Mehrass

{"title":"Comparison of biomarkers and laboratory results in unaffected, moderate, and severe COVID-19 recovered patients.","authors":"Sawsan Abuhammad, Karem H Alzoubi, Omar F Khabour, Shaher Hamaideh, Basheer Khassawneh, Amat Al-Khaleq O Mehrass","doi":"10.1080/20565623.2025.2559553","DOIUrl":"10.1080/20565623.2025.2559553","url":null,"abstract":"Aim: To compare several laboratory results, including liver function, lipid metabolism (HDL), pulmonary function, and hematological parameters among COVID-19 recovered patients who were divided into two groups (asymptomatic/mild vs. moderate/severe).Method: The sample consisted of patients matched by age and gender. These patients were divided into two groups. The first group consisted of mild or mild cases, and the second group included moderate and severe cases, classified based on their need for oxygen. Blood samples were collected from all participants, and analyses for complete blood count, liver function markers, kidney function markers, and lipid profiles were conducted at the Health Center of Jordan University of Science and Technology and King Abdullah University laboratories.Results: The analysis revealed Significant differences were noted in ALT (p = 0.002), DBC (p = 0.005), HDL (p = 0.035), Notably, the Forced Vital Capacity (FVC) showed a significant difference (F = 6.292, p = 0.012). The FEV1/FVC ratio was also highly significant (F = 45.054, p = 0.000).Conclusion: In this descriptive cohort study, the results indicating that specific biomarkers, such as elevated WBC and liver enzymes, are significantly associated with severe post-COVID outcomes. These findings highlight the systemic impact of the disease in severe cases, affecting multiple or one organ.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2559553"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12452437/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145080424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A systematic review of inflammatory bowel disease in Kazakhstan: prevalence, risk factors, and genetic insights. 哈萨克斯坦炎症性肠病的系统综述：患病率、危险因素和遗传见解。

IF 2.1

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-09-29 DOI: 10.1080/20565623.2025.2567152

Aigerim Japparkulova, Ainash Oshibayeva, Gulnaz Nuskabayeva, Karlygash Sadykova, Jamilya Kaibullayeva, Nursultan Nurdinov

{"title":"A systematic review of inflammatory bowel disease in Kazakhstan: prevalence, risk factors, and genetic insights.","authors":"Aigerim Japparkulova, Ainash Oshibayeva, Gulnaz Nuskabayeva, Karlygash Sadykova, Jamilya Kaibullayeva, Nursultan Nurdinov","doi":"10.1080/20565623.2025.2567152","DOIUrl":"10.1080/20565623.2025.2567152","url":null,"abstract":"Background: Inflammatory bowel disease is a chronic condition characterized by immune mediated inflammation and primarily includes Crohn's disease and ulcerative colitis.Objective: There is an increase rate of incidence of the disease in Kazakhstan. Therefore, it is important to determine the prevalence of the condition in to improve diagnosis and the treatment for the local population.Method: They current manuscript is a systematic review of the literature that focuses on IBD from Kazakhstan with a focus on prevalence, risk factors including genetic predisposition, disease mechanism, diagnosis and treatment.Results: The prevalence of IBD is higher in urban regions, and more prevalent in individuals under the age of 40 years. Genetic studies reported that familial IBD is quite rare in Kazakhstan, suggesting an environmental cause rather than a genetic reason that is driving the increase of prevalence.Conclusion: There are IBD-associated variants linked to immune function and inflammation pathways that may serve as noninvasive biomarkers for disease diagnosis and severity. However, the mechanisms of disease development and drug response may differ across different populations, therefore, there might be a need implement genetic testing to improve therapy and disease management in Kazakhstan.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2567152"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12482431/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy of combined immunotherapy and predictive role of inflammatory markers in elderly ESCC patients. 老年ESCC患者联合免疫治疗的疗效及炎症标志物的预测作用。

IF 2.1

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-09-29 DOI: 10.1080/20565623.2025.2564018

Bailong Liu, Guodong Nie, Rui Luo, Junjie Liu, Yang Ding, Mengyu Liu, Zhong Fan, Min Liu, Xiaonan Pang

{"title":"Efficacy of combined immunotherapy and predictive role of inflammatory markers in elderly ESCC patients.","authors":"Bailong Liu, Guodong Nie, Rui Luo, Junjie Liu, Yang Ding, Mengyu Liu, Zhong Fan, Min Liu, Xiaonan Pang","doi":"10.1080/20565623.2025.2564018","DOIUrl":"10.1080/20565623.2025.2564018","url":null,"abstract":"Aim: To assess the efficacy of immune checkpoint inhibitors (ICIs) combined with chemoradiotherapy and evaluate the prognostic value of peripheral inflammatory markers in elderly patients with inoperable esophageal squamous cell carcinoma (ESCC).Methods: A retrospective study of 124 elderly ESCC patients treated between 2021 and 2024. Patients were divided into immunotherapy and non-immunotherapy groups. Progression-free survival (PFS) was compared, and inflammatory markers were analyzed using Cox regression and ROC curves.Results: Median PFS was significantly longer in the ICI group (13.7 vs. 10.9 months, P = 0.043). Immunotherapy was an independent protective factor for PFS. Post-treatment NLR and PNI were predictive of outcomes in the ICI group.Conclusion: Combining ICIs with chemoradiotherapy improves survival in elderly inoperable ESCC patients. NLR and PNI may serve as accessible biomarkers to guide immunotherapy.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2564018"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12482436/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Personalized Combined Nutrition & Exercise Intervention in Newly Diagnosed Cancer Patients - a Trial Protocol. 新诊断癌症患者的个性化营养与运动联合干预-试验方案。

IF 2.1

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-10-09 DOI: 10.1080/20565623.2025.2564607

Sebastian Theurich, Timo Niels, Hansjoerg Baurecht, Christine Welker, Annika Tomanek, Ingo Schmidt-Wolf, Christine Greil, Kim Luley, Dirk Forstmeyer, Patrick Jahn, Johann Ockenga, Wibke Jensen, Katharina Graf, Joachim Wiskemann, Caterina Fiorentini, Nora Zoth, Michael Leitzmann, Freerk T Baumann

{"title":"Personalized Combined Nutrition & Exercise Intervention in Newly Diagnosed Cancer Patients - a Trial Protocol.","authors":"Sebastian Theurich, Timo Niels, Hansjoerg Baurecht, Christine Welker, Annika Tomanek, Ingo Schmidt-Wolf, Christine Greil, Kim Luley, Dirk Forstmeyer, Patrick Jahn, Johann Ockenga, Wibke Jensen, Katharina Graf, Joachim Wiskemann, Caterina Fiorentini, Nora Zoth, Michael Leitzmann, Freerk T Baumann","doi":"10.1080/20565623.2025.2564607","DOIUrl":"https://doi.org/10.1080/20565623.2025.2564607","url":null,"abstract":"The prevalences of malnutrition and sarcopenia are high already at the time of cancer diagnosis and significantly impact on treatment outcomes. Here, we present the protocol of a multicenter, randomized controlled trial to evaluate the efficacy of personalized, combined nutrition and physical exercise interventions in parallel to first-line cancer treatment. A total of 472 patients will be included and randomized into one of the two study arms. In the intervention arm (A) patients will receive an individualized, needs-adapted preventive and supervised nutritional and exercise program over at least four and up to six months in parallel to cancer treatment. In the control arm (B), patients receive recommendations for physical activity, prescriptions and nutrition counseling in a non-supervised manner. The physical and nutritional status, as well as quality of life will be analyzed in all patients by a multi-dimensional assessment program, termed resource-oriented needs assessment (RONA), before and at distinct time points during and after the intervention period. The primary combined endpoint will be the reduction of needs for supportive care defined by the RONA score at the end of the first-line cancer treatment or after six months of study intervention whichever comes first.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2564607"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145250699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

TWEAK/Fn14 axis may promote vascular smooth muscle cell senescence via p38 signaling pathway: preliminary evidence. TWEAK/Fn14轴可能通过p38信号通路促进血管平滑肌细胞衰老：初步证据

IF 2.4

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-01-22 DOI: 10.1080/20565623.2025.2455906

Chunyang Wei, Xiaoying Liu, Zhuang Miao, Hua Zhang, Yanfu Wang, Guoxian Qi

引用次数: 0

A study to determine the effect of nano-selenium and thymoquinone on the Nrf2 gene expression in Alzheimer's disease. 纳米硒和百里醌对阿尔茨海默病Nrf2基因表达影响的研究。

IF 2.4

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-01-31 DOI: 10.1080/20565623.2025.2458434

Doha El-Sayed Ellakwa, Laila Ahmed Rashed, Ola Sayed Ali, Noha Amr El-Sabbagh

{"title":"A study to determine the effect of nano-selenium and thymoquinone on the Nrf2 gene expression in Alzheimer's disease.","authors":"Doha El-Sayed Ellakwa, Laila Ahmed Rashed, Ola Sayed Ali, Noha Amr El-Sabbagh","doi":"10.1080/20565623.2025.2458434","DOIUrl":"10.1080/20565623.2025.2458434","url":null,"abstract":"Introduction: Alzheimer's disease is a developing public health concern in aging communities that affects a sizable section of the global population. The risk of Alzheimer's disease increases with age; it affects one-third of males and two-thirds of women. This research attempts to assess the effect of nano-selenium and thymoquinone on Nrf2 gene expression levels in Alzheimer's disease (AD).Methods: There were five identical groups of 50 albino male rats: a control group that was healthy; an AD positive control group; an AD group that received nano-selenium (5 mg/kg); an AD group that received thymoquinone (2 mg/kg); and an AD group that received both. The duration of treatment was 4 weeks. The levels of Nrf2 in brain tissues were evaluated using real-time PCR.Results: Nrf2 mean expression levels in the nano-selenium-treated rats, the thymoquinone-treated rats, and the rats that were given both treatments all increased significantly compared to AD rats with no treatment.Conclusions: This study showed that nano-selenium and thymoquinone elevated Nrf2 gene expression levels in AD.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2458434"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11792829/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reporting and representation of participant race and ethnicity in phase III clinical trials for solid tumors. 实体瘤III期临床试验中参与者种族和民族的报告和代表性。

IF 2.4

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-01-30 DOI: 10.1080/20565623.2025.2458415

Tianyi Wang, Dinorah J Villanueva, Ambily Banerjee, Dina Gifkins

{"title":"Reporting and representation of participant race and ethnicity in phase III clinical trials for solid tumors.","authors":"Tianyi Wang, Dinorah J Villanueva, Ambily Banerjee, Dina Gifkins","doi":"10.1080/20565623.2025.2458415","DOIUrl":"10.1080/20565623.2025.2458415","url":null,"abstract":"Background: Including racial and ethnic minorities in clinical trials is essential for advancing health equity. Despite progress, trials often do not mirror patient population demographics.Methods: The National Library of Medicine's Clinical Trials database was queried for phase III trials of lung, colorectal, breast, and prostate cancers. A reference population was identified from the Surveillance, Epidemiology, and End Result (SEER) database, covering 48% of the US population.Results: Among 181 trials, race and ethnicity data were included in 86.7% and 60.2% of trials, respectively, with improving reporting over time. Participants were predominantly White (76.3%), followed by Asian/Pacific Islander (14.1%), Black/African American (4.5%), and American Indian/Alaska Native (0.6%). Hispanic/Latino constituted 6.4% of participants. The proportion of non-White groups increased from 19.4% in trials started before 2011 to 26.2% after 2015. Compared with SEER data, the percentages were lower for Asian/Pacific Islander across all cancers, Black/African American in breast and prostate cancers, American Indian or Alaska Native in colorectal, breast, and prostate cancers in US solely trials.Conclusions: Reporting and enrollment of racial and ethnic minorities in trials remain inadequate but improving. To enhance diversity, real-world data are warranted to identify recruitment goals by better assessing the geographic distribution within the patient population.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2458415"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11792851/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Quantum leadership: new approach in managing shoulder dystocia in simulation-based training. 量子领导力：模拟训练中处理肩难产的新方法。

IF 2.4

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-01-30 DOI: 10.1080/20565623.2025.2458427

Georges Yared, Christopher Massaad, Kariman Ghazal

{"title":"Quantum leadership: new approach in managing shoulder dystocia in simulation-based training.","authors":"Georges Yared, Christopher Massaad, Kariman Ghazal","doi":"10.1080/20565623.2025.2458427","DOIUrl":"10.1080/20565623.2025.2458427","url":null,"abstract":"Background: Shoulder dystocia, a challenging condition for obstetricians, poses significant risks to both maternal and neonatal health, including maternal postpartum hemorrhage, neonatal hypoxia, and brachial plexus injury. Despite being unpredictable and unpreventable, effective management can mitigate these risks. Miscommunication and poor leadership are responsible for 72% of medical errors, which further highlights the importance of robust leadership skills in obstetric emergencies.Research design and methods: A qualitative study involving 20 participants through structured interviews assessed preferred leadership styles in managing shoulder dystocia.Results: Findings revealed that 55% of participants favored quantum leadership. Other preferences included laissez-faire by one anesthesiologist and democratic by two midwives. However, all participants acknowledged the efficacy of the seven quantum leadership skills in managing shoulder dystocia. Discussion emphasized that traditional leadership styles are less effective compared to quantum leadership in managing the complexities of shoulder dystocia. The quantum Ob-Wheel, consisting of 12 milestones, integrates these seven interdependent skills to guide the management process.Conclusions: Despite the limited sample size of this study, it is worth noting that, given the unpredictable nature of shoulder dystocia, clinicians should be prepared for its occurrence during any birth, with quantum leadership providing a strategic advantage in such scenarios.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2458427"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11792848/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Elevated expression of ANAPC1 in lung squamous cell carcinoma: clinical implications and mechanisms. ANAPC1在肺鳞状细胞癌中的表达升高：临床意义和机制

IF 2.4

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-03-26 DOI: 10.1080/20565623.2025.2482487

Xiao-Song Chen, Feng Chen, Shu-Jia He, Yi-Yang Chen, Bang-Teng Chi, Wan-Ying Huang, Yue Wei, Chun-Yan Zhao, Chang Song, Rong-Quan He, Gang Chen, Jin-Liang Kong, Hui-Ping Lu

{"title":"Elevated expression of ANAPC1 in lung squamous cell carcinoma: clinical implications and mechanisms.","authors":"Xiao-Song Chen, Feng Chen, Shu-Jia He, Yi-Yang Chen, Bang-Teng Chi, Wan-Ying Huang, Yue Wei, Chun-Yan Zhao, Chang Song, Rong-Quan He, Gang Chen, Jin-Liang Kong, Hui-Ping Lu","doi":"10.1080/20565623.2025.2482487","DOIUrl":"10.1080/20565623.2025.2482487","url":null,"abstract":"Aim: To investigate the comprehensive expression levels and possible molecular mechanisms of Anaphase Promoting Complex Subunit 1 (ANAPC1) in lung squamous cell carcinoma (LUSC).Methods: Data from 2,031 samples were combined to evaluate ANAPC1 mRNA levels, and 118 samples were collected for immunohistochemical (IHC) analysis. High-expression co-expressed genes (HECEGs) associated with ANAPC1 were analyzed for signaling pathways. Clinical significance, immune computations, and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) validation of ANAPC1's role in LUSC were assessed. Molecular docking evaluated binding affinity with potential therapeutics.Results: ANAPC1 mRNA was significantly upregulated in LUSC (SMD = 1.97, 95% CI [1.26-2.67]). Protein-level analysis confirmed this upregulation (p < 0.001). Most HECEGs associated with ANAPC1 were enriched in cell cycle pathways. Higher ANAPC1 expression correlated with poorer survival in LUSC patients (HR = 1.11, 95% CI: 1-1.49). ANAPC1 expression was higher in males and N1-stage vs. females and N0-stage; lower in grade I vs. II/III. Overexpression reduces immune cell infiltration and immunotherapy effectiveness, while knockdown inhibits cell proliferation. Drug sensitivity and docking analyses identified tenovin-1, carboxyatractyloside, and phycocyanobilin as potential antitumor agents targeting ANAPC1.Conclusion: The elevated expression of ANAPC1 might play a role in LUSC advancement and progression through its participation in cell growth-related pathways.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2482487"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11951694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143729534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0